Skip to main content
Top
Published in: Drugs 10/2021

Open Access 01-07-2021 | NSCLC | Correction

Correction to: Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC

Author: James E. Frampton

Published in: Drugs | Issue 10/2021

Login to get access

Excerpt

The article Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC, written by James E. Frampton, was originally published electronically in SpringerLink on 19 April 2021 without open access. After publication in volume 81, issue 6, pages 697–708, F. Hoffmann-La Roche requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by F. Hoffmann-La Roche. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by-nc/​4.​0/​. …
Metadata
Title
Correction to: Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC
Author
James E. Frampton
Publication date
01-07-2021
Publisher
Springer International Publishing
Published in
Drugs / Issue 10/2021
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-021-01542-w

Other articles of this Issue 10/2021

Drugs 10/2021 Go to the issue